Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - Solid Biosciences is a precision genetic medicine company focusing on Duchenne muscular dystrophy (DMD) and other genetic disorders [2][4] - The company is advancing its lead program, known as 003, which targets DMD, alongside programs for Friedreich's ataxia and various cardiac conditions [2][4] Company Overview - Solid Biosciences has developed multiple delivery technologies for gene therapy, including capsids, promoters, and dual plasmids [2] - The company aims to position its DMD program, 003, as a comprehensive solution in the competitive landscape of DMD gene therapy [4] Industry Context - The DMD landscape features numerous gene therapy programs, and Solid Biosciences is actively engaging in discussions to highlight the unique aspects of its offerings [3][4]